Haematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient's therapy course.
<h4>Background</h4>Mainly severe (CTCAE grade 3-4) haematotoxicity during peptide receptor radionuclide therapy (PRRT) is reported in literature due to major clinical impact, however moderate (CTCAE grade 2) haematotoxicity is common and could affect therapy management. The aim of this s...
Guardado en:
Autores principales: | Daphne M V de Vries-Huizing, Michelle W J Versleijen, Michiel Sinaasappel, Iris Walraven, Martine M Geluk-Jonker, Margot E T Tesselaar, Jeroen J M A Hendrikx, Berlinda J de Wit-van der Veen, Marcel P M Stokkel |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/49f0ebf26a2d4259ac04d82f4bf2bdd1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Haematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient’s therapy course
por: Daphne M. V. de Vries–Huizing, et al.
Publicado: (2021) - Molecular imaging and radionuclide therapy
-
Nephrotoxicity after radionuclide therapies
por: Ashwin Singh Parihar, et al.
Publicado: (2022) -
Targeted radionuclide therapy with astatine-211: Oxidative dehalogenation of astatobenzoate conjugates
por: David Teze, et al.
Publicado: (2017) -
Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours
por: Marianne S. Elston, et al.
Publicado: (2021)